---
title: "Arrowhead Pharmaceuticals Q3 2026 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294742236.md"
description: "Arrowhead Pharmaceuticals (ARWR) will report Q3 2026 earnings on August 4th after market close. Consensus estimates project an EPS of -$1.23 and revenue of $44.01M, a 91.9% year-over-year decline. Historically, the company has beaten EPS estimates 0% of the time and revenue estimates 25% of the time over the past year."
datetime: "2026-08-03T21:50:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294742236.md)
  - [en](https://longbridge.com/en/news/294742236.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294742236.md)
generator: "portal-rs"
---

# Arrowhead Pharmaceuticals Q3 2026 earnings preview

Arrowhead Pharmaceuticals (ARWR) is scheduled to announce Q3 earnings results on Tuesday, August 4th, after market close. The consensus EPS estimate is -$1.23 and the consensus revenue estimate is $44.01M (-91.9% Y/Y). Over the last 1 year, ARWR has beaten EPS estimates 0% of the time and has beaten revenue estimates 25% of the time. Over the last ...

### Related Stocks

- [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md)

## Related News & Research

- [Can Arrowhead Pharmaceuticals (ARWR) Still Look Like A Bargain Following Its Phase 3 SHASTA Data?](https://longbridge.com/en/news/298165580.md)
- [Arrowhead Pharmaceuticals (ARWR) Stock Looks Cheap On Cash Flow Yet Fair On Sales](https://longbridge.com/en/news/298117407.md)
- [Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials](https://longbridge.com/en/news/297536982.md)
- [Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of "Moderate Buy" by Analysts](https://longbridge.com/en/news/297869579.md)
- [Public Employees Retirement System of Ohio Makes New Investment in Arrowhead Pharmaceuticals, Inc. $ARWR](https://longbridge.com/en/news/298105697.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**